Sakamoto Teppei, Morishita Asahiro, Nomura Takako, Tani Joji, Miyoshi Hisaaki, Yoneyama Hirohiro, Iwama Hisakazu, Himoto Takashi, Masaki Tsutomu
Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, Miki‑cho, Kagawa 761‑0793, Japan.
Life Science Research Center, Kagawa University Faculty of Medicine, Miki‑cho, Kagawa 761‑0793, Japan.
Mol Med Rep. 2016 Oct;14(4):3350-6. doi: 10.3892/mmr.2016.5606. Epub 2016 Aug 9.
MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs that control the target gene translation by RNA interference; miRNAs are associated with cellular processes, including proliferation, differentiation, apoptosis, and cell survival. Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown etiology. One third of patients with PBC demonstrate suboptimal responses, which result in worse outcomes. It has been previously reported that miRNAs are involved in drug resistance, however, the association between miRNA expression levels and refractory PBC remains to be fully elucidated. In the present study, among the 20 patients with PBC treated with ursodeoxycholic acid or bezafibrate, 15 patients were classed as treatment‑effective, and 5 were classed as being treatment‑resistant. Using the miRNA array technique, miRNA profiles were identified for each group. A total of 35 miRNAs were significantly upregulated, and 23 were significantly downregulated in the treatment‑resistant group compared with the treatment‑effective group. In order to examine the association between the highly altered miRNAs and clinical features of the two groups, numerous parameters were analyzed. Elevated levels of direct bilirubin, aspartate transaminase (AST), and alanine transaminase (ALT) were identified to be associated with miRNA‑122 upregulation. AST, ALT, and γ guanosine triphosphate were additionally associated with miRNA‑378f upregulation. However, the reduction of miRNA‑4311 was associated with reduced levels of AST and ALT. miRNA‑4714‑3p was also negatively correlated with total bilirubin and lactate dehydrogenase. Therefore, identifying the miRNA profile was demonstrated to be a useful approach in the characterization of PBC development. It is suggested that highly altered miRNAs may be potential biomarkers for use in the development of treatment of patients with refractory PBC.
微小RNA(miRNA)是一类小的、内源性的非编码RNA,通过RNA干扰控制靶基因的翻译;miRNA与包括增殖、分化、凋亡和细胞存活在内的细胞过程相关。原发性胆汁性肝硬化(PBC)是一种病因不明的慢性胆汁淤积性肝病。三分之一的PBC患者表现出疗效欠佳,导致预后较差。此前有报道称miRNA与耐药性有关,然而,miRNA表达水平与难治性PBC之间的关联仍有待充分阐明。在本研究中,20例接受熊去氧胆酸或苯扎贝特治疗的PBC患者中,15例被归类为治疗有效,5例被归类为治疗抵抗。使用miRNA阵列技术,确定了每组的miRNA谱。与治疗有效组相比,治疗抵抗组共有35种miRNA显著上调,23种显著下调。为了研究高度改变的miRNA与两组临床特征之间的关联,分析了许多参数。直接胆红素、天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)水平升高与miRNA-122上调有关。此外,AST、ALT和γ-鸟苷三磷酸与miRNA-378f上调有关。然而,miRNA-4311的降低与AST和ALT水平降低有关。miRNA-4714-3p也与总胆红素和乳酸脱氢酶呈负相关。因此,确定miRNA谱被证明是表征PBC发展的一种有用方法。提示高度改变的miRNA可能是难治性PBC患者治疗开发中潜在的生物标志物。